Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
Ladetto
Marco
M
Cattedra di Ematologia, Via Genova 3, 10126 Torino, Italy. marco.ladetto@unito.it
Pagliano
Gloria
G
Ferrero
Simone
S
Cavallo
Federica
F
Drandi
Daniela
D
Santo
Loredana
L
Crippa
Claudia
C
De Rosa
Luca
L
Pregno
Patrizia
P
Grasso
Mariella
M
Liberati
Anna Marina
AM
Caravita
Tommaso
T
Pisani
Francesco
F
Guglielmelli
Tommasina
T
Callea
Vincenzo
V
Musto
Pellegrino
P
Cangialosi
Clotilde
C
Passera
Roberto
R
Boccadoro
Mario
M
Palumbo
Antonio
A
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D017024:Chemotherapy, Adjuvant; D016009:Chi-Square Distribution; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D015321:Gene Rearrangement; D050438:Genes, Immunoglobulin Heavy Chain; D006801:Humans; D007558:Italy; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction; D011719:Pyrazines / Q000008:administration & dosage; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000008:administration & dosage; D013997:Time Factors; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects
D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone